Navigation Links
ABBOTT PRISM

ProductsABBOTT PRISM
Company Abbott Diagnostics
Item ABBOTT PRISM
Features 
  • As the most automated screening transfusion instrument available, the ABBOTT PRISM instrument will reduce the risk of accidents, errors or tampering of results.
  • ABBOTT PRISM was specifically designed to improve and automate cGMP monitoring and reporting throughout the entire testing process.
  • ABBOTT PRISM reduces manual steps and operator intervention. ABBOTT PRISM increases throughput by running up to 960 tests per hour with STAT test capability in under one hour for all available assays.
  • Since 1996, countries have switched to ABBOTT PRISM for impressive safety, quality, productivity and reliability. There are over one hundred ABBOTT PRISM systems Test of Record internationally.
Description The ABBOTT PRISM is a fully automated, high-volume blood screening instrument designed to enhance the safety of the blood supply. Before a blood donation can enter the blood supply, it is tested for evidence of exposure to viruses that might cause disease. This screening process involves numerous assays, multiple test instruments and many manual steps. The ABBOTT PRISM instrument consolidates much of this testing into a single system, reducing the risk of accidents, errors and tampering by automating the manual testing procedures and steps currently used to screen blood.
Info Abbott Diagnostics
Customer Service: (847) 937-6100
Web site: http://www.abbottdiagnostics.com/

Related medicine products :

1. ABI PRISM 310 Genetic Analyzer
2. ABI PRISM 3100 Genetic Analyzer
3. ABI PRISM 7000 Sequence Detection System
4. ABI PRISM Optical Adhesive Covers
5. ABI PRISM Optical Adhesive Cover Starter Kit
6. ABI PRISM 7900HT Sequence Detection System
7. ABI PRISM® 3100-Avant Genetic Analyzer
Jewelers Forceps, delicate, straight....
2 mm wide tip with 1 mm by 4 mm eye. Curved shaft and ring handle with polished finish....
Straight iris forceps. Insulated....
Hardy bayonet forceps with stops. Insulated....
Medicine Products:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
(Date:6/24/2016)... ... 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ... raise to $12 an hour by 2020 and then adjusting it yearly to increase at ... the minimum wage, assure the wage floor does not erode again, and make future increases ...
(Date:6/24/2016)... ... 24, 2016 , ... Puradigm® & Innovative Solutions today announced ... and processing operations at its production facility, and opened its first two dispensaries ... manufacturer of a complete system of proactive air and surface purification solutions for ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology: